View Mobile Site

Ask the Expert

Signal Photos


Clinical study done for Afrezza

Posted: June 20, 2013 3:09 p.m.
Updated: June 20, 2013 3:09 p.m.

MannKind Corp. of Valencia has completed a phase three clinical study of its inhaled insulin therapy, Afrezza.

This clinical trial by the biomedical company was for patients with type 2 diabetes and is billed as the “next-generation” inhaler for patients whose disease is not well controlled with other medications.

The study also compares the new treatment to the traditional method of injecting insulin in patients.

MannKind plans to release the results of the data later this summer, and is expected to be the last major hurdle for the company to gain Food and Drug Administration approval.

Afrezza can treat both type 1 and 2 diabetes and is an ultra-rapid acting insulin therapy for the control of hyperglycemia, the company said.

The combined drug-device powder dissolves immediately upon inhalation and delivers insulin quickly to the blood stream.



Commenting not available.
Commenting is not available.


Powered By
Morris Technology
Please wait ...